Top-News

Evofem Biosciences Aktie News

Aktie
WKN:  A3D9Z3 ISIN:  US30048L3024 US-Symbol:  EVFM Branche:  Biotechnologie Land:  USA
0,0096 $
-0,0004 $
-4,00%
0,00824 € 21:42:31 Uhr
Depot/Watchlist
Marktkapitalisierung *
969,99 Tsd. €
Streubesitz
-
KGV
-
Index-Zuordnung
-

Evofem Biosciences News

21.11.25 - PR Newswire
Favorable Pricing Certificates Issued for Evofem's PHEXX by Emirates Drug Establishment are Launching Step for Commercialization in UAE
Favorable Pricing Certificates Issued for Evofem's PHEXX by Emirates Drug Establishment are Launching Step for Commercialization in UAE PR Newswire
13.11.25 - PR Newswire
Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update
Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update PR Newswire
20.10.25 - PR Newswire
Evofem Announces Voting Results from Special Meeting of Stockholders
Evofem Announces Voting Results from Special Meeting of Stockholders PR Newswire
01.10.25 - PR Newswire
Evofem's SOLOSEC Submitted for Marketing Approval in United Arab Emirates
Evofem's SOLOSEC Submitted for Marketing Approval in United Arab Emirates PR Newswire
26.09.25 - PR Newswire
Evofem Biosciences Honors World Contraception Day
Evofem Biosciences Honors World Contraception Day PR Newswire
11.09.25 - PR Newswire
Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms
Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms PR Newswire
09.09.25 - PR Newswire
Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting
Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting PR Newswire
21.08.25 - PR Newswire
Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law
Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-​passed Law PR Newswire
19.08.25 - PR Newswire
FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis
FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis PR Newswire
14.08.25 - PR Newswire
Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update
Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update PR Newswire
05.08.25 - PR Newswire
Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference
Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference PR Newswire
15.07.25 - PR Newswire
Phexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy
Phexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy PR Newswire
23.06.25 - PR Newswire
Evofem's PHEXXI Submitted for Marketing Approval in United Arab Emirates by Pharma 1 Drug Store
Evofem's PHEXXI Submitted for Marketing Approval in United Arab Emirates by Pharma 1 Drug Store PR Newswire
11.06.25 - PR Newswire
Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting
Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting PR Newswire
21.05.25 - PR Newswire
Evofem Signs SOLOSEC License Agreement for Middle East with Pharma 1
Evofem Signs SOLOSEC License Agreement for Middle East with Pharma 1 PR Newswire
15.05.25 - PR Newswire
Evofem Reports First Quarter 2025 Financial Results and Provides Business Update
Evofem Reports First Quarter 2025 Financial Results and Provides Business Update PR Newswire
14.04.25 - PR Newswire
Evofem Biosciences to Present at Emerging Growth Conference
Evofem Biosciences to Present at Emerging Growth Conference PR Newswire
26.03.25 - PR Newswire
Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics
Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics PR Newswire
24.03.25 - PR Newswire
Evofem Reports Fourth Consecutive Year of Net Sales Growth
Evofem Reports Fourth Consecutive Year of Net Sales Growth PR Newswire
13.02.25 - PR Newswire
Evofem Strengthens SOLOSEC Intellectual Property with New U.S. Patent from USPTO
Evofem Strengthens SOLOSEC Intellectual Property with New U.S. Patent from USPTO PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »